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Abstract
Background: Wegener granulomatosis (WG) belongs to the heterogeneous group of systemic vasculitides. The multifactorial
pathophysiology of WG is supposedly caused by yet unknown environmental influence(s) on the basis of genetic predisposition.
The presence of anti-neutrophil cytoplasmic antibodies (ANCA) in the plasma of patients and genetic involvement of the human
leukocyte antigen system reflect an autoimmune background of the disease. Strong associations were revealed with WG by
markers located in the major histocompatibility complex class II (MHC II) region in the vicinity of human leukocyte antigen
(HLA)-DPB1 and the retinoid X receptor B (RXRB) loci. In order to define the involvement of the 6p21.3 region in WG in more
detail this previous population-based association study was expanded here to the respective 3.6 megabase encompassing this
region on chromosome 6. The RXRB gene was analysed as well as a splice-site variation of the butyrophilin-like (BTNL2) gene
which is also located within the respective region. The latter polymorphism has been evaluated here as it appears as a HLA
independent susceptibility factor in another granulomatous disorder, sarcoidosis.
Methods: 150–180 German WG patients and a corresponding cohort of healthy controls (n = 100–261) were used in a two-
step study. A panel of 94 microsatellites was designed for the initial step using a DNA pooling approach. Markers with
significantly differing allele frequencies between patient and control pools were individually genotyped. The RXRB gene was
analysed for single strand conformation polymorphisms (SSCP) and restriction fragment length polymorphisms (RFLP). The
splice-site polymorphism in the BTNL2 gene was also investigated by RFLP analysis.
Results: A previously investigated microsatellite (#1.0.3.7, Santa Cruz genome browser (UCSC) May 2004 Freeze localisation:
chr6:31257596-34999883), which was used as a positive control, remained associated throughout the whole two-step approach.
Yet, no additional evidence for association of other microsatellite markers was found in the entire investigated region. Analysis
of the RXRB gene located in the WG associated region revealed associations of two variations (rs10548957 pallelic = 0.02 and
rs6531 pallelic = 5.20 × 10-5, OR = 1.88). Several alleles of markers located between HLA-DPB1, SNP rs6531 and microsatellite
1.0.3.7 showed linkage disequilibrium with r2 values exceeding 0.10. Significant differences were not demonstrable for the
sarcoidosis associated splice-site variation (rs2076530 pallelic = 0.80) in our WG cohort.
Conclusion: Since a microsatellite flanking the RXRB gene and two intragenic polymorphisms are associated significantly with
WG on chromosome 6p21.3, further investigations should be focussed on extensive fine-mapping in this region by densely
mapping with additional markers such as SNPs. This strategy may reveal even deeper insights into the genetic contributions of
the respective region for the pathogenesis of WG.
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Background
Wegener granulomatosis (WG) is a granulomatous disor-
der belonging to the heterogeneous group of systemic vas-
culitides (SV). A common feature of SV is the
inflammation of the endothelium [1,2]. SV are classified
according to the size of affected vessels and the type of
auto-antibodies, namely anti-neutrophil cytoplasmic
antibodies (ANCAs), which are used for differential diag-
nosis [3,4].
WG has an annual incidence of 5–10/million individuals
in Caucasians [5]. The pathophysiology of WG still
remains largely unknown with a supposedly multifacto-
rial basis [6,7]. Presence of ANCA in the plasma of ~90%
of WG patients reflects autoimmune background of the
disease. In WG patients ANCAs are mostly directed against
proteinase 3 (PRTN3), presented in primary azurophil
granules of polymorph nuclear neutrophils (PMN) and
lysosomes of monocytes [8,9]. After cytokine priming of
PMN, PRTN3 translocates to the cell surface where ANCAs
can bind and activate PMN resulting in a respiratory burst
and release of proteolytic enzymes [10]. This may then
lead to a self sustaining inflammatory process.
Several candidate genes such as PRTN3, α1-antitrypsine,
adhesion molecule CD18 or interleukin 1 and its receptor
have been investigated for WG association [11-15]. In
addition, there is genetic evidence that the human leuko-
cyte antigen (HLA) system is involved in WG develop-
ment [16-19]. Yet, mostly these studies showed
exclusively spurious WG associations. Recently, an
extended association screen (EAS) revealed strong WG
association of a microsatellite marker (UCSC May 2004
Freeze chr6:31257596-34999883) located in major histo-
compatibility complex class II (MHCII) region in the
immediate vicinity of the HLA-DPB1 and retinoid X recep-
tor β (RXRB) genes in two German populations [20]. Gen-
otyping 19 alleles of the HLA-DPB1 gene with increased
frequency of the HLA-DPB1*0401  allele supported the
evidence that this region harbours at least one genetic fac-
tor for WG. But further association mapping encompass-
ing a region of ~280 kb with additional microsatellite and
SNP markers did not allow to decide between several
alternatives. Either this region harbours one major locus
for WG, encompasses two susceptibility loci or the associ-
ation of specific marker alleles is due to linkage with a
causative locus at some distance. In this context, the com-
plex linkage disequilibrium (LD) patterns are crucial with
areas of densely packed recombination hot spots as well
as large LD blocks on chromosome 6p thus further com-
plicating to define associations in this region [21,22]. In a
recent study on the granulomatous disorder sarcoidosis, a
fine mapping approach using SNPs led to the definition of
an HLA independent genetic factor, BTNL2  [23]. This
study underlines the necessity of investigations on larger
regions encompassing defined associations in order to
evaluate aforementioned considerations on extended LD
on chromosome 6, i.e. how far an association can extend,
or HLA independent risk factors. Here, we expanded asso-
ciation mapping to a 3.6 mb region encompassing the
WG associated 6p21.3 as well as adjacent regions with
additional microsatellites. This study was carried out in a
two-step population based design using pooled DNA for
the initial scan and, subsequently individual genotyping
of markers that differed statistically significantly between
WG patients and controls.
Furthermore, we focussed on two candidate genes on
chromosome 6, RXRB  and  butyrophilin-like 2 (BTNL2)
located in the vicinity or even in the respective WG-asso-
ciated region [20]. RXRB presents as a good candidate as
the protein binds to hormone nuclear receptors such as
the vitamin D receptor (VDR) [24]. VDR and its ligand cal-
citriol have widespread influence on immuno-regulatory
systems [25-28]. Thereby, RXRB  variation may be
involved in the pathogenesis of WG. In order to find func-
tionally relevant polymorphisms the entire coding region
and ~593 bp of the promoter were screened for variations.
Furthermore, a recently described splice-site polymor-
phism of the BTNL2 gene has been reported to represent
a HLA independent risk factor for another granulomatous
disorder affecting the lung, namely sarcoidosis [23].
BTNL2 is located on 6p21.3 in the vicinity of the HLA-
DRB1 locus. On the basis of sharing traits in WG and sar-
coidosis such as granulomas and pulmonary affections,
the functionally relevant splice-site polymorphism was
genotyped in our cohorts.
Methods
Patients
German WG patients were clinically diagnosed according
to international standards by applying the 1990 classifica-
tion criteria of the American College of Rheumatology
[29] and the definitions of the 1994 Chapel Hill Consen-
sus Conference [3]. All patients have defined ANCA-status
(npositive = 151; nnegative = 30). WG was biopsy-proven in
the German reference centre for vasculitis (Department of
Pathology, University of Schleswig-Holstein Campus Lue-
beck, Germany) by 2 different observers. Control groups
comprised healthy adults from northern Germany and the
Ruhr area (Germany). The institutional Ethics Committee
of Bochum Ruhr-University approved this study.
Informed consent was obtained from all individuals.
Pooling of DNA
DNA pooling was performed as described before [20].
Briefly, DNA concentrations were measured spectropho-
tometrically in 4 steps, and samples were diluted accord-
ingly. The final DNA concentration in pools was 50 ng/µl.
In order to control for artefacts during pooling, 150BMC Medical Genetics 2006, 7:21 http://www.biomedcentral.com/1471-2350/7/21
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ANCA-positive patients were divided into 3 sub-pools and
100 controls from the northern German cohort into 2
sub-pools, respectively.
Microsatellite marker panel
A panel of 94 markers was designed encompassing the
WG associated 6p21.32 and flanking regions (annotated
by Santa Cruz genome browser (UCSC):
chro6:31255920-34938760, May 2004 freeze, see [30]).
Microsatellites were chosen utilizing the simple-repeat
option of UCSC. The average distance between microsat-
ellite markers was 41 kb (standard deviation ~30 kb) with
five gaps of distances ≥100 kb (<152 kb). Most of the mic-
rosatellites harboured dinucleotide repeats (68%), the
remaining comprised tri-, tetra- or penta-nucleotide
repeat motifs. Further information about the microsatel-
lites is available as additional file 1 (website: [31]). No
marker revealed significantly differing 'intra sub-pool' dis-
tributions as reflected by the p value (see below).
PCR
For fragment analysis we used fluorescence 5'FAM
labelled, tailed oligonucleotide added to the 5'-part of the
sequence specific primer as described before [20]. Primers
were designed with the Primer Express 2.0 Software
(Applied Biosystems, Foster City, USA). Melting tempera-
ture was set to 55°C. Three primers were used for PCR:
tailed forward primer (tailed F), reverse primer and
labelled primer (labelled F) corresponding to the 5'-tail
sequence of tailed F. Reaction mix consisted of 1 × PCR
buffer (Qiagen GmbH, Hilden, Germany), 1.5 pmol
labeled F, 0.2 mM each dNTP, 3 mM MgCl2, 0.2 pmol
tailed F, 1.5 pmol reverse primer, 0.25 U Qiagen Hot Start
Taq (Qiagen) and 50 ng DNA. PCR was performed in a
Biometra T-Gradient Thermoblock (Biometra, Göttingen,
Germany) using the following characteristics: activation
step at 95°C for 15 min; 35 cycles of denaturation at 95°C
for 1 min, annealing at 55°C for 1 min and extension at
72°C for 1 min; and a final extension at 72°C for 10 min.
Initial screen
Electrophoresis and data analysis were performed on a 48-
well ABI377 slab-gel system using ABI Genotyper software
as described before [20]. Data analysis generated marker-
specific allele image profiles (AIPs) representing distribu-
tions of alleles within each sub-pool.
Statistical analysis
AIPs of WG pools were compared with those of the con-
trol cohort. Peak heights were cumulated to 100% (repre-
senting 100 alleles in each pool, respectively). Afterwards
allele frequencies (corresponding to peaks height) were
calculated according to the estimated total allele count.
Association was tested for each marker by comparison of
the AIPs from WG-DNA pools with those of controls by
contingency tables using a significance level of p = 0.05. In
order to focus the statistics on major effects, alleles with a
frequency of less than 5% were summarized to one allele.
Next, frequency distributions were compared by means of
contingency tables as mentioned above. The resulting p
values were corrected for multiple testing using QValue
software [32,33] with a 'cut off' of 5%. Nevertheless, non-
corrected p values were simply ranked according to their
evidence for association in order to select markers for fur-
Table 1: Oligonucleotides and restriction enzymes used for SSCP analyses of the exonic and 593 bp promoter regions of the RXRB 
gene.
Exon Oligonucleotide sense/antisense PCR product (bp) Restriction enzyme; 
length of fragments 
(bp)
01a CGGTATCCCTACTCTCAGCCA/GCGGGATCCAGCCAGG 164 -
01b GGTGCGAAAAGAAATGCA/CACTGGCTCGCCTGCC 202 -
02 CTCTTGTGTGTCTGTGTGCCT/
GGTTAGAGGATTGGAAGGTCA
403 AvaII 176/227
03 GACTTCCCTATTTCCCCCAT/TCTCGGAGAAGAGGAGGCT 207 -
04 TGAAGGTGTCTCCATGCAAC/AGAAGGGCATGTGGTCTAAGA 275 BsmFI 126/149
05 CTGATGAGGCCGTAAGGATA/GTGGATTGACCCCAACACT 280 Eco24I 130/150
06 TCCATAACTCTTACCCCCGT/CTGGGTACGCAAGGTAAGG 255 MboII 102/153
07 CCTGATTTCTGGCTCCTGAC/CCTCTATCTACATGCCAGCCT 209 -
08 GCTGAGCTGTGACCTTTGAGT/TCTCGGAGAAGAGGAGGCT 199 -
09 CTCCTCTCTTCCCTGCCAT/CCTCATAGCACTCCCCACC 199 -
10 CTCAATCCCCTTCTCCCAC/AGTGTGAGAAGCACCACGTC 209 -
Promoter (593 bp)
Sys1 GGGCTTAATTCGACCCAA/GCATTTCTTTTCGCACC 213 -
Sys2 GCTAACAGGCCGGAGGAGA/GGATTGATCGGAGGATTAGCT 212 -
Sys3 CTCTCCTTTCCCGGTTTG/TCGTCTAGTTGGAAACCGAG 234 -
Sys4 CTCTTTATCCCGAACCACCT/TCTCGCGGGATCTAAAGG 221 -
Sys5 CATCACGCTGACCAGAGG/TGGTGAAAGATTAGTGTCCCA 214 -BMC Medical Genetics 2006, 7:21 http://www.biomedcentral.com/1471-2350/7/21
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ther studies. In addition, intra-population differences
were tested by comparing WG pools with each other as
well as both control pools.
Individual genotyping
In order to exclude false positive significances, patients
and controls were individually genotyped for respective
markers. Genotyping was performed on the Beckman
Coulter CEQ8000 8-capillary system using 'Fragment
Analysis Module' software (Beckman Coulter, Inc., Fuller-
ton, USA). Reaction mix contained 1 × PCR buffer (Qia-
gen), 0.75 pmol fluorescent labelled F, 0.2 mM each
dNTP, 3 mM MgCl2, 0.2 pmol tailed F, 1.5 pmol reverse
primer, 0.25 U Qiagen Hot Start Taq (Qiagen) and 50 ng
DNA. Parameters for amplification were used as described
above. Allele and genotype frequency of WG patients and
controls were compared by χ2-testing. Additionally,
Hardy-Weinberg equilibrium was tested using Genepop
software [20].
Screening of the coding and a 593 bp promoter region in 
the RXRB gene
The coding and promoter regions (593 bp) of the RXRB
gene were initially screened by single strand conformation
polymorphism (SSCP) with 48 patient (ANCA-positive)
and 48 control DNAs. The RXRB  sequence was down-
loaded from UCSC database (NM021976, July 2003
Freeze). Oligonucleotides were designed using Primer
Express 2.0 Software (Applied Biosystems) with an opti-
mal annealing temperature of 57°C (see table 1). PCR was
performed using Qiagen HotStar Taq (Qiagen) with an
initial denaturation at 95°C for 15 min, 35 cycles of 94°C
for 30 sec -57°C for 30 sec -72°C for 30 sec and a final
extension at 72°C for 10 min. PCR conditions were cho-
sen as recommended by Qiagen. Fragments were labelled
with α-dATP (exons 2–10; Hartmann Bioanalytics, Braun-
schweig, Germany) and α-dCTP (exon 1a and 1b; Hart-
mann Bioanalytics). SSCP were analysed on 6% and 5%
polyacrylamide gels with either 5% or 10% glycerol. The
gels were run at room temperature at 35 W. Amplificates
containing obvious band shifts were sequenced using dye
terminator cycle sequencing on an ABI377 automatic
sequencer (Applied Biosystems). Statistical comparisons
of allele frequencies and genotypes were based on the χ2
test. In addition, Hardy-Weinberg equilibrium has been
tested for all SNPs.
Genotyping of rs6531
The sequence variation rs6531 was genotyped in 151
ANCA-positive patients and 201 controls by RFLP analy-
sis. A restriction site for DdeI (NewEnglandBiolabs, Ips-
wich, USA) was generated by using the tailed mismatch
oligonucleotide, mmantisense-CATCGCTGATTCGCACAT-
CATCAATGGATCGGTCTGA. PCR was performed by 'the
tailed primer' method using three oligonulceotides: the
mmantisene-primer, an oligonucleotide corresponding to
the tail and the forward oligonucleotide sense-
CCGATCTTTAGTGACCCCAGT. Restriction with DdeI
results in a 226 bp fragment (T allele) and in case of the C
allele in 2 fragments of 192 and 34 bp, respectively. Elec-
trophoresis was done on a 3% agarose gel containing
ethidium bromide. The results were analysed with the χ2
test and Hardy-Weinberg equilibrium was controlled.
Genotyping of the Val95Ala polymorphism in the RXRB 
gene
The previously reported the Val95Ala polymorphism [34]
was genotyped by RFLP analysis in 94 patients and 90
controls. Fragments were amplified using oligonucle-
otides Val95Ala sense-CGGTGGGGTATTAGAGAATT and
Val95Ala antisense-CCCATGGAAGAACTGATGACTGG.
PCR was performed with Qiagen HotStar Taq (Qiagen) as
described above with an annealing temperature of 55–
60°C and different MgCl2-concentrations generating a
300bp fragment. The 2 alleles (Val, T allele; Ala, C allele)
are detected as 232 bp and 193 bp bands, respectively.
Electrophoresis was done in ethidium bromide contain-
ing 2% agarose gels. In order to control the results of the
RFLP analysis, DNAs of 15 patients and 20 controls were
sequenced as described above. Association was verified
with the χ2 test and Hardy-Weinberg equilibrium.
Genotyping the functionally relevant BTNL2 variation 
rs2076530
Primer extension analysis was used to genotype the trun-
cating splice site mutation in 180 patients and 261 con-
trols. Two primers were designed for amplification,
forward TCCAGATACTCAGTGCCAGA, reverse: TTGTC-
CAGGAACTAGCATATT. PCR conditions were: 1 × PCR
buffer (Qiagen), 0.2 mM each dNTP, 0.2 pmol forward
primer, 0.2 pmol reverse primer, 0.25 U Qiagen Hot Start
Taq (Qiagen) and 50 ng DNA. The reaction was per-
formed with initial denaturation at 95°C for 15 min, 35
cycles of 94°C for 30 sec -60°C for 30 sec -72°C for 30 sec
and a final extension at 72°C for 10 min The product was
purified with magnetic beads system (AMPure; ABgene,
Epsom, UK). A primer extension reaction was performed
with the interrogation primer: GCCCAGTTTGGATCT-
GAAGGTGGTA using Beckmann CEQ™ SNP-Primer
Extension Kit (Beckman Coulter) under recommended
conditions. Electrophoresis and data analysis was per-
formed using Beckman Coulter CEQ8000. Statistical anal-
ysis was based on the χ2 tests, and allele frequencies were
tested for Hardy-Weinberg equilibrium.
LD analyses
We calculated pair-wise LD between HLA-DPB1  alleles
(genotypes obtained from a previous study [20], see addi-
tional file 2, website: [35]), rs6531 and the significantlyBMC Medical Genetics 2006, 7:21 http://www.biomedcentral.com/1471-2350/7/21
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associated microsatellite #1.0.3.7 in our control and
patient cohorts. Microsatellite, SNP and HLA-DPB1 alleles
with frequencies below 0.05 were excluded. For pairwise
LD calculation we presumed each microsatellite allele to
be biallelic, i.e. one distinct allele against all others
pooled. The same procedure was applied for the most fre-
quent  HLA-DPB1  alleles *0401, *0402, *0201 and
*0301. The strength of LD between all three markers was
quantified by D' and r2 values. LD analyses were calcu-
lated by Haploview 3.2 [36].
Results
Initial association mapping
Eighty four markers were analysed in an initial scan (after
exclusion of non-polymorphic and recurrently artefact-
producing microsatellites). Thereof, five microsatellites
revealed significant differences in allele distribution
between WG patients and controls (see table 2). Correc-
tion for multiple comparisons with QValue rejected sig-
nificance for all results. Nonetheless, markers were simply
ranked according to their p values. Thereafter, four mark-
ers were selected for individual genotyping (see figure 1).
One microsatellite showed only marginal significance
(#1.0.3.4) after summation of rare alleles (<5%) and thus
was excluded from further investigations. Individual gen-
otyping confirmed exclusively one marker (adjacent to
RXRB), the positive control, as statistically significantly
different: #1.0.3.7 (p = 3 × 10-4, see table 2).
Analyses of the RXRB gene
SSCP analyses in the RXRB gene did not reveal any varia-
tions in exons 1–5, 8–10 and the 593 bp promoter region.
Similarly, the Val95Ala polymorphism was neither detect-
able by RFLP nor by sequence analyses in our patient and
control cohorts. Yet, the analysis of the PCR product com-
prising exon 6 revealed a band shift. Subsequent sequenc-
ing showed an intronic CT-INDEL polymorphism which
has been reported before (rs10548957). Statistical analy-
sis of the allele frequencies revealed a p value of 0.02 with
a minor allele frequency of 0.07 in the control cohort (n
= 47) and total absence in the patients (n = 43). In exon 7
a single nucleotide polymorphism (SNP) (rs6531) was
detected using SSCP and sequencing. Comparison of
allele frequencies of patients (n = 151) vs. controls (n =
201) revealed significant p values (see table 3 for detailed
analyses). Additionally 28 ANCA-negative patients were
genotyped for this SNP and compared to either the ANCA-
positive patients or the control cohort. There is a signifi-
cant deviation between the ANCA-negative and -positive
patients regarding this SNP. The ANCA-negative cohort
did not differ from the control group.
LD analyses
Several alleles between HLA-DPB1, rs6531 and microsat-
ellite marker #1.0.3.7 showed LD with r2 values exceeding
0.10 (for detailed description see figure 2A and 2B). For
example, strong LD exists between HLA-DPB1*0401 and
microsatellite allele *3 as well as the rs6531 polymor-
phism in the patient and control cohorts.
Table 2: P values for microsatellite markers after the initial step and individual genotyping.
p values
Code of marker Number of alleles after analysis with pooled 
DNA
after summation of rare 
alleles (<5%)
#1.0.0.1 5 0.02 0.01
#1.0.0.5 12 0.03 0.01
#1.0.3.4 3 0.04 0.05
#1.0.3.7* 5 2 × 10-4 3 × 10-4
#1.0.4.1 6 1 × 10-4 4 × 10-4
p values
Code of marker after analyses of each single 
allele (most significant allele)
after individual genotyping (pc 
value)
after correction by Q-value
#1.0.0.1 0.03 n.s. n.s.
#1.0.0.5 >0.05 n.s. n.s.
#1.0.3.4 0.03 n.d. n.d.
#1.0.3.7* < 1 × 10-4 4 × 10-5 (pc = 3 × 10-4; c = 5) n.s.
#1.0.4.1 3 × 10-3 n.s. n.s.
n.s. = not significant; n.d. = not determined; * = positive controlBMC Medical Genetics 2006, 7:21 http://www.biomedcentral.com/1471-2350/7/21
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Analysis of the functionally relevant BTNL2 variation
Genotyping of rs2076530 polymorphism in 180 patients
and 261 controls (Northern Germany and Ruhr area pop-
ulations) did not reveal any statistically significant differ-
ence in allele, phenotype and genotype frequencies
between all WG patients and healthy individuals (see
table 4). In addition, when dividing the patient cohort
into ANCA+ and ANCA-patients, significant differences
were not detected between the respective patient and con-
trol cohorts (data not shown).
Discussion
The approach using pooled DNA and allele image profiles
for microsatellite based association studies was used to
investigate groups of candidate genes for different multi-
factorial disorders revealing novel predisposition factors
for respective diseases [20,37]. For these studies markers
were chosen located intra- or juxtagenically to distinct
genes. Here, we used a population based association study
approach with microsatellites and DNA pooling for scan-
ning a ~3.6 mb region on 6p21.3. This chromosomal seg-
ment includes the previously characterized, WG
associated region [20]. Several other studies have revealed
associations of HLA genes with WG and other vasculitides
(e.g. [17,19,38-41]). Yet, most of these results could not
be replicated. Considering the highly variable HLA com-
plex, the strong positive selection effects on this region in
combination with the relatively limited number of inves-
tigated patients, definitive conclusions are truly challeng-
ing. By using our EAS approach we searched for further
loci for WG or whether the identified HLA-DPB1/RXRB
associations are due to linkage with other factors located
more distantly on 6p21.3 comprised in the genomic
region investigated here. Yet, we could neither reveal any
Map of the investigated HLA region with p values of the markers used in the initial screen Figure 1
Map of the investigated HLA region with p values of the markers used in the initial screen. Figure shows the inves-
tigated fragment of chromosome 6 comprising the previously defined WG associated region encompassing the HLA-DPB1 and 
RXRB genes. Vertical lines represent studied microsatellites. The lengths/heights of these lines correspond to p values after 
analyses in the initial screen with pooled DNA. The 4 markers, which were genotyped individually, are labelled. The p values of 
markers #1.0.0.1, #1.0.0.5 and #1.0.4.1 (pool analysis) could not be replicated by genotyping individually. Drawn in red is the 
marker (#1.0.3.7) that remained significantly different after individual genotyping. This marker has been used as a positive con-
trol (see text). For further information of fine localisation of each investigated marker and inter-marker distances see addi-
tional file 1.
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evidence for an additional locus nor for an expanded, sig-
nificantly associated 'HLA-DPB1/RXRB' region, respec-
tively. In our study, the only marker (#1.0.3.7) which
remained significantly associated has been reported
before [20]. This marker is located in the immediate vicin-
ity of the RXRB gene and ~125 kb centromeric to HLA-
DPB1. Hence we calculated LD of the microsatellite, HLA-
DPB1 alleles (with data from a previous study [20]; see
additional file 2) and the significantly differing, intragenic
rs6531 RXRB SNP. These analyses e.g. confirmed results of
Rajisbaum et al. [42] which revealed significant LD
between polymorphisms in RXRB  and  HLA-DPB1. In
order to definitively investigate this very locus, a more
detailed approach with a dense map of additional markers
(preferential SNPs) appears mandatory.
It remains possible, that loci of small effects escaped
detection in our microsatellite-based association mapping
Table 3: Genotyping of rs6531 in the RXRB gene.
Genotypes/phenotypes/alleles Patients ANCA+ (n = 151) Patients ANCA- (n = 36) Controls (n = 201)
CC 36 15 92
CT 87 19 88
TT 28 2 21
CC+CT (vs. TT) 123 34 180
TT+CT (vs. CC) 115 21 109
C 159 49 272
T 143 23 130
ANCA+ against ANCA- patients ANCA+ patients against controls
Genotypes/phenotypes/alleles
P value OR (95 % C.I.) P value OR (95 % C.I.)
CC 0.03 2.3 × 10-5
CT 0.10 1.91 (0.87 to 4.16)* 1.6 × 10-4 2.53 (1.55 to 4.11)*
TT 0.02 5.83 (1.23 to 27.65)* 0.03 5.89 (3.01 to 11.53)*
CC+CT (vs. TT) 0.07 0.26 (0.06 to 1.14) 0.03 0.51 (0.29 to 0.94)
TT+CT (vs. CC) 0.03 2.26 (1.17 to 4.88) 2.3 × 10-5 2.70 (1.69 to 4.30)
C 1.0 × 10-2 5.2 × 10-5
T 1.91 (1.11 to 3.30) 1.88 (1.38 to 2.56)
OR = odds ratio, C.I. = confidence interval.
*Odds ratios for the CT and TT genotypes are contrasted against the CC genotype. No evidence for statistical difference between the ANCA-
negative WG patients and the control cohort was revealed, when calculating all off above-used comparisons.
Table 4: Genotyping of rs2076530 in the BNTL2 gene.
Genotypes/phenotypes/alleles Patients *1 (n = 180) Controls (n = 261) P value
GG 68 79 0.27
GA 76 135 0.14
AA 36 47 0.94
GG+GA 144 214 0.84
AA+GA 112 182 0.19
G 212 293 0.80
A 148 229
*1 ANCA positive (n = 150) and ANCA negative (n = 30) patients. No statistically significant difference between the ANCA positive and negative 
patients was evident.BMC Medical Genetics 2006, 7:21 http://www.biomedcentral.com/1471-2350/7/21
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Graphical overview of LD analyses with frequent HLA-DPB1 alleles, the rs6531 polymorphism in the RXRB gene and alleles of  the significantly WG-associated #1.0.3.7 microsatellite marker Figure 2
Graphical overview of LD analyses with frequent HLA-DPB1 alleles, the rs6531 polymorphism in the RXRB 
gene and alleles of the significantly WG-associated #1.0.3.7 microsatellite marker. Pair-wise LD evaluated by D' 
and r2 between markers in the previously found WG associated chromosome 6 region for controls (2A) and patients (2B). Ver-
tical lines with circle, triangle and square represent the relative localisation of each tested marker (HLA-DPB1, RXRB rs6531 and 
microsatellite marker #1.0.3.7, respectively). D' and r2 values are indicated by colour coding. Logarithm of odds (LOD) values 
equal to or exceeding 2 are represented by dashed rectangles, circles or squares. Rectangles are related to LDs between the 
microsatellite #1.0.3.7 and HLA-DPB1 alleles. Circles represent LD values between HLA-DPB1 and the SNP. Squares show LDs 
between the microsatellite alleles and rs6531 SNP. The investigated alleles of the microsatellite markers are shown at the left 
hand side of the figure, whereas the different designations of the HLA-DPB1 alleles are depicted at the right hand side. MS: mic-
rosatellite.
2A
2BBMC Medical Genetics 2006, 7:21 http://www.biomedcentral.com/1471-2350/7/21
Page 9 of 11
(page number not for citation purposes)
– a procedure known to ascertain strong associations.
Such deficiency might be due to artefacts in the pooling
procedure and analyses with pooled DNA such as length-
dependent amplification of short microsatellite marker
alleles or even the presence of null-alleles. In addition, the
slab-gel system approach might reflect a further hindrance
in this subtle procedure, since it is not 100% consistent.
Altogether such shortcomings could result in false allele
frequencies thus ignoring truly positive low-effect loci, for
which extremely precise data are necessary. A further
explanation for the negative results for most markers is
that our panel may not represent the whole region com-
pletely. Hence the possibility remains that we missed
causative alleles due to lack of LD between a distinct
marker allele and the respective susceptibility factor. More
detailed information on haplotype block structures and
future definition of LD between multiallelic microsatellite
markers may facilitate even more far-fetched interpreta-
tions of our analyses. Nevertheless, our data indicate that
the here investigated region might harbour only one
(major) locus associated with WG as represented by the
control marker in the vicinity of RXRB (~5 kb) showing a
positive result. By applying QValue correction tests, the
significance of this marker would have been rejected. Sim-
ilar controversies were presented recently in a study for
narcolepsy utilizing EAS using correction according to
Bonferroni [37]. Hence, further analyses on this region
were performed regardless of the correction for multiple
comparisons.
In addition to the indirect association study with micros-
atellites, we screened the entire coding (including the
splice-sites) and the promoter region of RXRB in order to
seek putative functionally relevant variations. In these
analyses two polymorphisms were evident: an intronic
CT-INDEL (rs10548957) variation revealing only a mar-
ginal association with WG, whereas the synonymous SNP
(rs6531) in exon 7 was strongly associated (table 3). Nev-
ertheless, this latter SNP does not affect known functional
sequences influencing splicing and or regulation of gene
expression. Therefore, the functional consequences of
both polymorphisms are not immediately apparent. Both
variations, however, confirmed the previously defined
predisposing and protective haplotypes [20]. In this study
only part of the potential promoter region was investi-
gated. Therefore, the expression of RXRB may be influ-
enced by polymorphisms/mutations in more distant
promoter regions. Interestingly, the SNP in exon 7 might
reflect differences between ANCA-negative and -positive
patients. Whereas this polymorphism is associated in the
ANCA-positive WG group, there is no statistical difference
between the controls and ANCA-negative patient group.
Although the amount of ANCA-negative patients in our
study is rather small and therefore the statistics are almost
underpowered, this result gives a further hint that both
phenotypes may differ in their genetic background con-
firming recent studies, e.g. on the intracellular tyrosine phos-
phates (PTPN22) gene [43].
Although our initial mapping approach did not reveal an
association in further regions in the HLA  complex, we
genotyped the previously found functionally relevant var-
iation in the BTNL2 gene, which is associated with sar-
coidosis and may present a predisposing/protective
variation with low effect size [23]. Recently, several stud-
ies proposed common genetic factors for diseases charac-
terised by autoimmune phenomena such as
polymorphisms in the aforementioned PTPN22 gene or
the cytotoxic T lymphocyte associated protein (CTLA4; see
[44,45]). Considering common features of sarcoidosis
and WG (e.g. autoimmune background, granulomata in
the lung), variations within BTNL2 may represent risk fac-
tors for WG. Yet, in our study we did not find evidence for
involvement of BTNL2 in the pathogenesis of WG, neither
in the initial screen (both microsatellites flanking BTNL2
at ~25 kb: #1.0.2.5 and #1.0.2.6 showing p = 0.95 and p
= 0.63, respectively) nor in individual genotyping with the
functional rs2076530 polymorphism reported before (p =
0.42, table 4). As a remote possibility, different variations
(of low effect size) in the BTNL2 gene may have predis-
posing/protective nature in the pathogenesis of WG due
to allelic heterogeneity.
Conclusion
Based on our largely negative association data in context
with the defined WG associated region on 6p21.3, we sub-
mit that only a single region of ~280 kb exists that is
responsible for WG predisposition in the HLA complex.
In case several loci of low effect size would exist, novel
alternative methodological approaches are necessary to
validate their association with WG on chromosome 6.
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